Therefore, there is a major need for additional studies on early-phase post-stroke BBB disruption, how tPA contributes to it, and where to therapeutically target this pathological mechanism to increase the therapeutic window of tPA and ultimately improve stroke outcome. This evidence concerns the gene PLAT and stroke disorder.